{"contacts": [{"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Daniel Liebler"}, {"accession": "MS:1000589", "name": "contact email", "value": "daniel.liebler@protypia.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Protypia, Inc"}]}, {"terms": [{"accession": "MS:1002037", "name": "dataset submitter"}, {"accession": "MS:1000586", "name": "contact name", "value": "Ryan Morrison"}, {"accession": "MS:1000589", "name": "contact email", "value": "ryan.morrison@protypia.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Protypia, Inc"}]}], "description": "New therapeutics targeting immune checkpoint proteins have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level quantitation of drug targets presents a critical problem.  We used multiplexed, targeted mass spectrometry (MS) to quantify the immunotherapy target proteins PD-1, PD-L1, PD-L2, IDO1, LAG3, TIM-3, VISTA, GITR, and CD40 in formalin-fixed, paraffin-embedded (FFPE) NSCLC specimens.  Immunohistochemistry (IHC) and MS measurements for PD-L1 were weakly correlated, but IHC did not distinguish protein abundance differences detected by MS.  PD-L2 abundance exceeded PD-L1 in over half the specimens and the drug target proteins all displayed different abundance patterns.  mRNA correlated with protein abundance only for PD-1, PD-L1, and IDO1 and tumor mutation burden did not predict abundance of any protein targets.  Global proteome analyses identified distinct proteotypes associated with high PD-L1-expressing and high IDO1-expressing NSCLC.  MS quantification of multiple drug targets and tissue proteotypes can improve clinical evaluation of immunotherapies for NSCLC.", "fullDatasetLinks": [{"accession": "MS:1002873", "name": "Panorama Public dataset URI", "value": "https://panoramaweb.org/hULkB7.url"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD019061"}, {"accession": "MS:1002872", "name": "Panorama Public dataset identifier", "value": "https://panoramaweb.org/hULkB7.url"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "FFPE NSCLC PRM"}], "modifications": [{"accession": "UNIMOD:4", "name": "Carbamidomethyl"}, {"accession": "UNIMOD:259", "name": "Label:13C(6)15N(2)"}, {"accession": "UNIMOD:267", "name": "Label:13C(6)15N(4)"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "32555523"}, {"accession": "MS:1002866", "name": "Reference", "value": "Liebler DC, Holzer TR, Haragan A, Morrison RD, O\u2019Neill Reising L, Ackermann BL, Fill JA, Schade AE, Gruver AM. Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer. Sci Rep [Internet]. 2020;10(1):9805. Available from: https://doi.org/10.1038/s41598-020-66902-0"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer"}